In Biomarkers We Trust?  

Oleh:

Baker, Mona

Jenis: Article from Journal - ilmiah internasional
Dalam koleksi: Nature Biotechnology: The Science and Business of Biotechnology vol. 23 no. 3 (Mar. 2005), page 297-304.
Topik: DRUG; biomakers

Ketersediaan

Perpustakaan Pusat (Semanggi) Nomor Panggil: NN9.2 Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

The omics revolution offers plenty of decision making tools. It's knowing how to use them that's key. What drug and diagnostic companies want, more than anything, is the ability to predict the future. Rather than waiting years and studying thousands of patients, they want to be able to tell who has a disease, which patients will benefit from what drug and whether a drug will have unintended consequences. Predictive tests are starting to come onto the market. Last December, the US Food and Drug Administration (FDA) approved the first DNA microarray test, the amplichip cytochrome P450 genotyping test, developed by roche molecular systems of pleasanton, california, which gauges how quickly an individual will metabolize a range of drugs, thereby helping physicians select the optimal drug and dosage...

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali